Get the Stockscreener App
22.44
1.45%
0.32
Pre-market:
22.53
0.09
+0.40%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $22.44, with a volume of 51.74M.
It is up +1.45% in the last 24 hours and down -12.75% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$22.12
Open:
$22.17
24h Volume:
51.74M
Relative Volume:
1.14
Market Cap:
$127.27B
Revenue:
$63.63B
Net Income/Loss:
$8.03B
P/E Ratio:
15.91
EPS:
1.41
Net Cash Flow:
$9.84B
1W Performance:
+2.75%
1M Performance:
-12.75%
6M Performance:
-23.78%
1Y Performance:
-13.39%
1-Day Range:
$22.12
$22.93
1-Week Range:
$20.91
$22.93
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
22.44 | 127.27B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India
TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight Loss Pill? - Yahoo Finance
Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com
Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus
Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus
Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com
Pfizer Ends Development of Its Obesity Pill - Time Magazine
Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun
Pfizer ends development of potential pill obesity treatment - The Journal Gazette
Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Health Care Up on Defensive DemandHealth Care Roundup - MarketScreener
Obesity Drug Developers Rise on M&A Hopes After Pfizer Setback - Bloomberg
Pfizer halts development of weight loss pill after liver injury report - KFXL
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our Valuation - Morningstar
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg
Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review - Mega Doctor News
Pfizer ends development of weight-loss pill after patient's liver injury - upi.com
Thoracic Radiculopathy Market Is Booming Worldwide 2025-2032 | Pfizer Inc.,Johnson Johnson (DePuy Synthes) - openPR.com
Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure? - The Globe and Mail
Pfizer’s Danuglipron Is Done, Sparking M&A Speculation - insights.citeline.com
PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
Pfizer (NYSE:PFE) Discontinues Danuglipron Development After Safety Review in Study - Yahoo Finance
What's Pfizer's next move after shelving its oral obesity drug danuglipron? - Endpoints News
Pfizer shelves obesity pill plan after patient suffers liver injury during clinical trial - Firstpost
Morgan Stanley maintains Pfizer stock at $31 target post-Danu halt - Investing.com
Pfizer Inc. (PFE): “Dead Money… Close the Casket,” Says Jim Cramer - Insider Monkey
Pfizer will end development of daily anti-obesity pill due to liver injury - The Hill
Pfizer drops obesity pill development after liver injury report - Yahoo Finance
Pfizer Stops Work on Oral GLP-1 Obesity Drug After Safety Signal Surfaces in Clinical Trial - MedCity News
Alert on Ageas SA's share offering tagged to Pfizer withdrawn - MarketScreener
Structure Therapeutics shares rise on Pfizer’s obesity drug exit - Investing.com
Pfizer scraps experimental GLP-1 receptor after patient injury - Medical Marketing and Media
PFIZER INC : UBS reiterates its Neutral rating - MarketScreener
Viking Therapeutics (VKTX) Surges as Pfizer Halts Obesity Drug - GuruFocus
Safety worries spur Pfizer to drop another obesity pill - BioPharma Dive
Pfizer ends development of weight-loss pill danuglipron - Reuters
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):